ValuEngine cut shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a strong sell rating in a research report report published on Friday.
Several other brokerages also recently issued reports on GALT. HC Wainwright upped their price objective on Galectin Therapeutics from $3.50 to $6.00 and gave the company a buy rating in a research report on Tuesday, November 28th. Roth Capital assumed coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They issued a buy rating and a $8.00 price objective on the stock. Seaport Global Securities restated a buy rating and issued a $5.00 price objective on shares of Galectin Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a hold rating to a buy rating and set a $2.75 price objective on the stock in a research report on Thursday, November 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Galectin Therapeutics has an average rating of Buy and an average price target of $4.75.
Shares of Galectin Therapeutics (GALT) opened at $2.48 on Friday. Galectin Therapeutics has a 12-month low of $0.84 and a 12-month high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. equities research analysts anticipate that Galectin Therapeutics will post -0.52 EPS for the current year.
Several large investors have recently modified their holdings of the company. KCG Holdings Inc. lifted its position in shares of Galectin Therapeutics by 1.9% in the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock valued at $198,000 after acquiring an additional 1,592 shares in the last quarter. Northern Trust Corp lifted its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares during the period. Virtu KCG Holdings LLC lifted its position in Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after buying an additional 21,008 shares during the period. Advisor Group Inc. lifted its position in Galectin Therapeutics by 7.4% during the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock worth $1,112,000 after buying an additional 35,850 shares during the period. Finally, Vanguard Group Inc. lifted its position in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after buying an additional 134,165 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.
WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/galectin-therapeutics-galt-stock-rating-lowered-by-valuengine.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.